Terns Pharmaceuticals (NASDAQ:TERN) CEO Amy Burroughs Sells 14,583 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CEO Amy Burroughs sold 14,583 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $39.19, for a total transaction of $571,507.77. Following the sale, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at $11,324,969.44. This trade represents a 4.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Terns Pharmaceuticals Trading Down 0.6%

Shares of TERN opened at $39.35 on Thursday. The company has a market cap of $4.08 billion, a price-to-earnings ratio of -38.20 and a beta of -0.28. The business’s fifty day simple moving average is $38.52 and its two-hundred day simple moving average is $21.95. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $48.26.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TERN. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the third quarter worth about $42,807,000. Vestal Point Capital LP purchased a new position in Terns Pharmaceuticals during the 4th quarter valued at approximately $181,800,000. Janus Henderson Group PLC bought a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $136,496,000. Capitolis Liquid Global Markets LLC purchased a new stake in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $123,026,000. Finally, Lord Abbett & CO. LLC bought a new position in shares of Terns Pharmaceuticals during the 4th quarter valued at approximately $109,581,000. Institutional investors own 98.26% of the company’s stock.

Wall Street Analyst Weigh In

TERN has been the topic of a number of recent analyst reports. William Blair raised shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, November 3rd. BMO Capital Markets increased their price objective on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Truist Financial boosted their target price on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Citizens Jmp raised their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Terns Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $58.11.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.